Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NVAX |
---|---|---|
09:32 ET | 103936 | 12.35 |
09:34 ET | 43718 | 12.29 |
09:36 ET | 24339 | 12.345 |
09:38 ET | 16687 | 12.3803 |
09:39 ET | 18170 | 12.4109 |
09:41 ET | 11480 | 12.4 |
09:43 ET | 20440 | 12.48 |
09:45 ET | 30813 | 12.44 |
09:48 ET | 61345 | 12.31 |
09:50 ET | 16044 | 12.363 |
09:52 ET | 8799 | 12.37 |
09:54 ET | 20754 | 12.4101 |
09:56 ET | 19258 | 12.35 |
09:57 ET | 12748 | 12.355 |
09:59 ET | 10809 | 12.35 |
10:01 ET | 42405 | 12.26 |
10:03 ET | 37782 | 12.25 |
10:06 ET | 68057 | 12.205 |
10:08 ET | 38193 | 12.23 |
10:10 ET | 8697 | 12.22 |
10:12 ET | 11098 | 12.1677 |
10:14 ET | 11116 | 12.1941 |
10:15 ET | 18658 | 12.18 |
10:17 ET | 9077 | 12.225 |
10:19 ET | 23725 | 12.2499 |
10:21 ET | 14934 | 12.24 |
10:24 ET | 4769 | 12.24 |
10:26 ET | 21650 | 12.165 |
10:28 ET | 40102 | 12.21 |
10:30 ET | 20699 | 12.2 |
10:32 ET | 11280 | 12.205 |
10:33 ET | 12396 | 12.245 |
10:35 ET | 13450 | 12.22 |
10:37 ET | 6560 | 12.2 |
10:39 ET | 7917 | 12.25 |
10:42 ET | 4290 | 12.24 |
10:44 ET | 26622 | 12.3 |
10:46 ET | 7618 | 12.27 |
10:48 ET | 8610 | 12.28 |
10:50 ET | 7089 | 12.31 |
10:51 ET | 17162 | 12.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Novavax Inc | 1.8B | -3.9x | --- |
PTC Therapeutics Inc | 2.4B | -4.0x | --- |
ACADIA Pharmaceuticals Inc | 2.6B | -1,236.2x | --- |
Azenta Inc | 2.8B | -19.0x | --- |
P3 Health Partners Inc | 177.8M | -0.9x | --- |
Catalyst Pharmaceuticals Inc | 1.8B | 28.0x | --- |
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8B |
---|---|
Revenue (TTM) | $996.6M |
Shares Outstanding | 140.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.97 |
EPS | $-3.18 |
Book Value | $-5.14 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 1.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.